IDO1 and osteosarcoma: Given the fact that IDO1 is highly expressed on Ewing sarcoma cells and has been associated with worse outcome in osteosarcoma, among other cancers 160, 161, combining such IDO inhibitors with immunotherapy may provide significant therapeutic benefit for those patients.